-
Mashup Score: 5FDA-Approved Isotope Therapies Provide 2 Options in the Castration-Resistant Prostate Cancer Armamentarium - 19 hour(s) ago
Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 1
Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Elraglusib in combination with GnP demonstrated a statistically significant improvement in OS vs GnP alone as a first-line treatment for patients with metastatic PDAC. #pcsm https://t.co/w9Z1ZnJPWT https://t.co/FgYNWhB5MG
-
-
Mashup Score: 3Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world - 4 day(s) ago
Investigators found that benefits of treatments that are observed in trials also appear in the real world.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Stephen J. Freedland, MD, (@SFreedlandMD) discusses the benefits of mCRPC treatments translating to the real-world. @CS_Urology #pcsm https://t.co/O57OhqF6nC
-
-
Mashup Score: 3
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer. #pcsm | @DrScottTagawa @AmerUrological https://t.co/FjX8RzSKsQ
-
-
Mashup Score: 1
“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Joy Maulik, CRNP, discusses the importance of genetic testing in prostate cancer. @ChesUrology #pcsm https://t.co/nEvWtYOJwG
-
-
Mashup Score: 0
Initial study results may be available as soon as the first half of 2026.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The first patients have been enrolled in a phase 2 trial of (177Lu) rhPSMA-10.1 injection for mCRPC. #pcsm https://t.co/2RQcsQh86D
-
-
Mashup Score: 3
A panelist discusses how these comparative results could influence clinical decision-making by suggesting potentially different magnitudes of benefit between enzalutamide and darolutamide depending on disease volume, with the treatment effect differences possibly being more pronounced in high-volume disease patients, although individual patient factors should still guide personalized therapy selection.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Arun Azad, MD, (@AzadOncology) discusses the impact of disease volume on treatment selection in prostate cancer. @PeterMacCC #pcsm https://t.co/IhiCSLdkOR
-
-
Mashup Score: 4PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC - 8 day(s) ago
Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Michael J. Morris, MD, of @MSKCancerCenter broke down efficacy and safety data from the phase 3 PSMAfore trial that supported the expanded approval of lutetium Lu 177 vipivotide tetraxetan for select patients with PSMA+ metastatic mCRPC. #PCSM https://t.co/jiP9jhmFUv https://t.co/NzkRIdl5Kj
-
-
Mashup Score: 0
A recommendation from an independent data monitoring committee prompted the discontinuation of the phase 3 CAPItello-280 trial.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Developer AstraZeneca has announced the discontinuation of the phase 3 CAPItello-280 trial evaluating capivasertib plus docetaxel and androgen deprivation therapy among patients with metastatic castration-resistant prostate cancer. #pcsm # https://t.co/Xh3vpPzYLp
-
-
Mashup Score: 1
The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The phase 3 CAPItello-280 trial, assessing the safety and efficacy of adding capivasertib to docetaxel and ADT in mCRPC, has been discontinued following a recommendation from the IDMC. #pcsm https://t.co/tvLgwGvphm
-
Findings from ongoing clinical trials, such as the phase 3 PEACE III and the PSMAfore studies, have demonstrated an emergence of promising agents for patients with CRPC, including radium-223 and Pluvicto, respectively. @YungLyou @Providence #pcsm https://t.co/dmfhbcIk7q https://t.co/xnI6gvPc8X